Novel NMR Technique for In-Vitro Toxicity Testing of a 3D Cancer Model

Q3 Pharmacology, Toxicology and Pharmaceutics
M. Alwahsh, Robert Knitsch, R. Marchan, J. Lambert, E. Tolstik, H. Raschke, Dina Mahadaly, Alexander Marx, Djeda Belharazem, R. Hergenröder
{"title":"Novel NMR Technique for In-Vitro Toxicity Testing of a 3D Cancer Model","authors":"M. Alwahsh, Robert Knitsch, R. Marchan, J. Lambert, E. Tolstik, H. Raschke, Dina Mahadaly, Alexander Marx, Djeda Belharazem, R. Hergenröder","doi":"10.35516/jjps.v16i2.1529","DOIUrl":null,"url":null,"abstract":"The metabolic pathogenesis of thymic carcinomas (TCs) is poorly understood and adjuvant therapy has limited success in metastatic disease and tumor recurrence. Most studies on TCs use two-dimensional (2D) cell culture models, which are not considered as physiologically relevant, and consequently translation to the in-vivo situation remains challenging. Tissue-specific architecture, based in part on interactions with the microenvironment is an essential component of tumors and may be better recapitulated in three-dimensional (3D) cell culture models. Therefore, our goal is to establish 3D thymoma models which will then be used to understand the pharmacokinetics and pharmacodynamics of anticancer drug therapy via metabolic profiling of living cells. Our novel approach using NMR allows for the measurement of small tissue-like models, which are normally not feasible with standard analytical techniques. The currently-available methods only provide a “snap-shot” of the measured time point and tend to be destructive, e.g. dissecting or optical cleaning of the specimen to gain 3D Information – a limitation we overcome with our current method using NMR spectroscopy. In addition, anticancer therapy is only partially effective, mainly due to inherent or drug-induced resistance of tumor cells to standard chemotherapeutics and radiotherapy. Therefore, novel therapeutic strategies are urgently needed.","PeriodicalId":14719,"journal":{"name":"Jordan Journal of Pharmaceutical Sciences","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Jordan Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35516/jjps.v16i2.1529","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

The metabolic pathogenesis of thymic carcinomas (TCs) is poorly understood and adjuvant therapy has limited success in metastatic disease and tumor recurrence. Most studies on TCs use two-dimensional (2D) cell culture models, which are not considered as physiologically relevant, and consequently translation to the in-vivo situation remains challenging. Tissue-specific architecture, based in part on interactions with the microenvironment is an essential component of tumors and may be better recapitulated in three-dimensional (3D) cell culture models. Therefore, our goal is to establish 3D thymoma models which will then be used to understand the pharmacokinetics and pharmacodynamics of anticancer drug therapy via metabolic profiling of living cells. Our novel approach using NMR allows for the measurement of small tissue-like models, which are normally not feasible with standard analytical techniques. The currently-available methods only provide a “snap-shot” of the measured time point and tend to be destructive, e.g. dissecting or optical cleaning of the specimen to gain 3D Information – a limitation we overcome with our current method using NMR spectroscopy. In addition, anticancer therapy is only partially effective, mainly due to inherent or drug-induced resistance of tumor cells to standard chemotherapeutics and radiotherapy. Therefore, novel therapeutic strategies are urgently needed.
三维癌症模型体外毒性测试的新型核磁共振技术
胸腺癌(TCs)的代谢发病机制尚不清楚,辅助治疗在转移性疾病和肿瘤复发中的成功率有限。大多数关于tc的研究使用二维(2D)细胞培养模型,这被认为不具有生理学相关性,因此将其转化为体内情况仍然具有挑战性。部分基于与微环境相互作用的组织特异性结构是肿瘤的重要组成部分,可能在三维(3D)细胞培养模型中得到更好的概括。因此,我们的目标是建立3D胸腺瘤模型,然后通过活细胞的代谢谱来了解抗癌药物治疗的药代动力学和药效学。我们使用核磁共振的新方法允许测量小的类组织模型,这通常是不可行的标准分析技术。目前可用的方法只提供测量时间点的“快照”,并且往往具有破坏性,例如解剖或光学清洗标本以获得3D信息-我们使用核磁共振波谱法克服了当前方法的限制。此外,抗癌治疗仅部分有效,主要是由于肿瘤细胞固有或药物诱导的对标准化疗和放疗的耐药性。因此,迫切需要新的治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Jordan Journal of Pharmaceutical Sciences
Jordan Journal of Pharmaceutical Sciences Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
1.70
自引率
0.00%
发文量
33
期刊介绍: The Jordan Journal of Pharmaceutical Sciences (JJPS) is a scientific, bi-annual, peer-reviewed publication that will focus on current topics of interest to the pharmaceutical community at large. Although the JJPS is intended to be of interest to pharmaceutical scientists, other healthy workers, and manufacturing processors will also find it most interesting and informative. Papers will cover basic pharmaceutical and applied research, scientific commentaries, as well as views, reviews. Topics on products will include manufacturing process, quality control, pharmaceutical engineering, pharmaceutical technology, and philosophies on all aspects of pharmaceutical sciences. The editorial advisory board would like to place an emphasis on new and innovative methods, technologies, and techniques for the pharmaceutical industry. The reader will find a broad range of important topics in this first issue.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信